Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2014 June;105(3) > Minerva Medica 2014 June;105(3):229-35





A Journal on Internal Medicine

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236




Minerva Medica 2014 June;105(3):229-35

language: English

Increased serum levels of some inflammatory markers in patients with multiple sclerosis

Uysal S. 1, Meriç Yilmaz F. 1, 2, Boğdaycioğlu N. 1, Mungan Öztürk S. 3, Ak F. 3

1 Clinic of Biochemistry, Ankara Numune Education and Research Hospital, Ankara, Turkey;
2 Department of Biochemistry, Yildirim Beyazit University Medical Faculty, Ankara, Turkey;
3 Clinic of Neurology, Ankara Numune Education and Research Hospital, Ankara, Turkey


AIM: As known multiple sclerosis (MS) is a chronic neuroinflammatory progressive disease. The aim of this study was to assess some inflammatory markers in MS patients and their relationships with clinical subgroups and disability status.
METHODS: The serum levels of procalcitonin (PCT), YKL-40, IFN-γ and TNF-α were measured by an ELISA microplate reader in 59 MS patients and in 29 healthy subjects.
RESULTS: Mean serum PCT and TNF-α levels were significantly higher in patients with MS than control group (P<0.001). Serum YKL-40 and IFN-γ concentrations were elevated in MS group compared the healthy subjects, but the difference was not significantly. CIS, RRMS and SPMS groups had higher levels of PCT and TNF-α than control group. YKL-40 levels were positively correlated with EDSS score (r=0.412, P=0.001). IFN-γ and TNF-α levels were found to be negatively correlated with EDSS score (r=-0.347, P=0.007 and r=-0.328, P=0.011, respectively).
CONCLUSION: Increased levels of these inflammatory markers might provide important contributions to the underlying inflammatory pathways in MS.

top of page

Publication History

Cite this article as

Corresponding author e-mail